GlassScriptPhysician profile
Michael K Rosenthal
NPI 1487744421
$20,075.88
in general payments reported to CMS, 2019-2025
37 companies · $3,247 in 2025
The $3,247 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,399 · 2020: $1,665 · 2021: $3,457 · 2022: $2,713 · 2023: $3,214 · 2024: $3,380 · 2025: $3,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,821 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,820.59 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,527.04 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,642.61 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,578.72 | 2019-2025 | |
| Amgen INC. | $1,362.78 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,328.11 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,226.48 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $1,215.70 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $1,058.09 | 2019-2022 | |
| Genzyme Corporation | $1,037.32 | 2019-2025 | |
| Pfizer INC. | $1,028.91 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $920.83 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $756.32 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $639.02 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $527.26 | 2021-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $523.29 | 2019-2025 | Siliq, Cabtreo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $394.97 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $394.17 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $332.86 | 2019-2020 | |
| Galderma Laboratories, L.P. | $290.10 | 2019-2025 | Nemluvio, Aklief |
| Merz North America, INC. | $228.37 | 2025 | |
| Celgene Corporation | $193.70 | 2019 | |
| Organon LLC | $127.43 | 2025 | Vtama |
| Almirall LLC | $114.65 | 2019-2024 | Klisyri |
| Epi Health, LLC | $113.57 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $89.56 | 2021 | |
| Vyne Pharmaceuticals INC. | $75.21 | 2020 | |
| Paratek Pharmaceuticals, INC. | $72.68 | 2022-2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.92 | 2023-2025 | Cyltezo, Spevigo |
| Dermira, INC. | $49.60 | 2019-2021 | |
| Strata Skin Sciences, INC. | $36.35 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.78 | 2024 | Ycanth |
| Sandoz INC. | $22.22 | 2023 | Hyrimoz |
| Biofrontera INC. | $21.39 | 2025 | |
| Fresenius Kabi USA, LLC | $20.88 | 2024 | Idacio |
| Encore Dermatology INC. | $17.27 | 2019 | |
| Nabriva Therapeutics, Plc | $16.50 | 2021 | |
| Lnhc, INC | $15.22 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.